Archives
|
Entry
|
Blogger
|
Date
▴
|
Location
|
|
Anadys Shares Boom on Hepatitis C Finding
|
Luke Timmerman |
01/08/09 |
San Diego
|
|
Hepatitis C Drug From Anadys Shows Quick Virus-Killing Punch
|
Luke Timmerman |
01/08/09 |
San Diego
|
|
ZymoGenetics’ New Boss Sees Parallels to Dark Days at Immunex
|
Luke Timmerman |
01/05/09 |
Seattle
|
|
Ligand Cuts Another Deal With GlaxoSmithKline
|
Luke Timmerman |
12/18/08 |
San Diego
|
|
Luck, Curiosity, Naivete: The Essential Ingredients of Innovation
|
Luke Timmerman |
12/16/08 |
Seattle
|
|
Seattle Genetics Drug Fights Hodgkin’s, Frazier Sounds Off on Biotech Ventures, SBRI Pushes Malaria Vaccine, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
12/11/08 |
Seattle
|
|
Avila Comes Out of Stealth to Talk Bonds, Covalent Bonds
|
Luke Timmerman |
12/08/08 |
Boston
|
|
FDA Gives Fast-Track Status to Anadys’ Hepatitis C Drug Candidate
|
Bruce V. Bigelow |
12/03/08 |
San Diego
|
|
Biotech Survival Index: Boston Life Sciences Companies Brace for Long, Hard Winter
|
Luke Timmerman |
11/25/08 |
Boston
|
|
Tysabri’s Roots at the “Hutch,” MediQuest Spurned by FDA, ZymoGenetics Drug Passes Test, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
11/06/08 |
Seattle
|
|
ZymoGenetics Drug For Hepatitis C Kills Virus with Minimal Side Effects
|
Luke Timmerman |
11/03/08 |
Seattle
|
|
Vertex Drug for Hepatitis C Shows Durable Virus-Killing Ability in Tough-to-Treat Patients
|
Luke Timmerman |
11/01/08 |
Boston
|
|
Anadys Drug Found Safe in Small Study, Aims to Contend in New Class of Hepatitis C Meds
|
Luke Timmerman |
11/01/08 |
San Diego
|
|
Vertex Gears up for Big Liver Disease Conference
|
Luke Timmerman |
10/29/08 |
Boston
|
|
ZymoGenetics’ Kidney Cancer Drug, Taken with Nexavar, Shrinks Tumors in Relapsed Patients
|
Luke Timmerman |
10/22/08 |
Seattle
|
|
ZymoGenetics “Sleeper” Wakes Up, Leroy Hood Unveils New Company, CMC Icos Expands, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/02/08 |
Seattle
|
|
ZymoGenetics “Sleeper” for Hepatitis C Aims to Wipe Out Side Effects of Anti-Viral Therapy
|
Luke Timmerman |
09/30/08 |
Seattle
|
|
Cocrystal Discovery Raises $10 Million To Make Pills Against Viral Infections
|
Luke Timmerman |
09/19/08 |
Seattle
|
|
Vertex Raises $191 Million in Stock Offering
|
Luke Timmerman |
09/18/08 |
Boston
|
|
Vertex To Sell 7 Million Shares of Stock
|
Luke Timmerman |
09/17/08 |
Boston
|
|
Vertex Fending Off Competitors By Treating the Toughest Patients With Hepatitis C
|
Luke Timmerman |
09/09/08 |
Boston
|
|
ZymoGenetics Hands Over Atacicept Rights to Partner, Merck KGaA
|
Luke Timmerman |
09/03/08 |
Seattle
|
|
Vertex Drug Poised for Pivotal Trial Among Patients Who Fail Prior Hepatitis C Treatments
|
Luke Timmerman |
08/19/08 |
Boston
|
|
ZymoGenetics Drug Getting Off to Slow Start in Marketplace
|
Luke Timmerman |
08/06/08 |
Seattle
|
|
Vertex Marching Ahead With Cystic Fibrosis Program
|
Luke Timmerman |
08/01/08 |
Boston
|
|
Dicerna Pharmaceuticals Raises Another $8.4 Million for Next-Generation RNAi
|
Luke Timmerman |
07/15/08 |
Boston
|
|
Immune Design Aiming To Make Vaccines That Work Better in a Single Shot
|
Luke Timmerman |
07/07/08 |
Seattle
|
|
Vertex’s Hepatitis C Drug Passes Test, Moving to Another Phase III
|
Luke Timmerman |
06/09/08 |
Boston
|
|
Vertex Falls On Hepatitis Drug Delay Reports
|
Robert Buderi |
01/04/08 |
Boston
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2008 Xconomy. All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
